Sesen Bio Inc
F:PCBK
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
N/A
N/A
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PCBK stock under the Base Case scenario is 0.7375 EUR. Compared to the current market price of 0.5124 EUR, Sesen Bio Inc is Undervalued by 31%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Sesen Bio Inc
Run backtest to discover the historical profit from buying and selling PCBK based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Sesen Bio Inc
Balance Sheet Decomposition
Sesen Bio Inc
Current Assets | 189.1m |
Cash & Short-Term Investments | 166.9m |
Receivables | 825k |
Other Current Assets | 21.4m |
Non-Current Assets | 30k |
Other Non-Current Assets | 30k |
Current Liabilities | 31m |
Accounts Payable | 1.2m |
Accrued Liabilities | 29.4m |
Other Current Liabilities | 354k |
Earnings Waterfall
Sesen Bio Inc
Revenue
|
40m
USD
|
Operating Expenses
|
-26.4m
USD
|
Operating Income
|
13.6m
USD
|
Other Expenses
|
-33.5m
USD
|
Net Income
|
-19.9m
USD
|
Free Cash Flow Analysis
Sesen Bio Inc
USD | |
Free Cash Flow | USD |
PCBK Profitability Score
Profitability Due Diligence
Sesen Bio Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Sesen Bio Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
PCBK Solvency Score
Solvency Due Diligence
Sesen Bio Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Sesen Bio Inc's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PCBK Price Targets Summary
Sesen Bio Inc
According to Wall Street analysts, the average 1-year price target for PCBK is 2.25 EUR .
Shareholder Yield
Current shareholder yield for PCBK is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
PCBK Price
Sesen Bio Inc
Average Annual Return | -5.82% |
Standard Deviation of Annual Returns | 28.81% |
Max Drawdown | -93% |
Market Capitalization | 103.9m EUR |
Shares Outstanding | 202 756 992 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2014-02-06. The firm's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process. The Company’s advanced product candidate Vicinium, also known as VB4-845, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of bacillus calmette-guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
Contact
IPO
Employees
Officers
The intrinsic value of one PCBK stock under the Base Case scenario is 0.7375 EUR.
Compared to the current market price of 0.5124 EUR, Sesen Bio Inc is Undervalued by 31%.